Obe-cel for relapsed/refractory B-ALL: The FELIX study
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
Summary
During the ALL Hub Steering Committee meeting in April 2026, Daniel DeAngelo led a discussion on the latest findings from the phase Ib/II FELIX trial (NCT04404660) investigating obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The discussion featured contributions from Ibrahim Aldoss, José María Ribera, André Baruchel, Wendy Stock, and Nicolas Boissel.
This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.